OncoImmunology (Jun 2017)

CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer

  • Jieyao Li,
  • Liping Wang,
  • Xinfeng Chen,
  • Lifeng Li,
  • Yu Li,
  • Yu Ping,
  • Lan Huang,
  • Dongli Yue,
  • Zhen Zhang,
  • Fei Wang,
  • Feng Li,
  • Li Yang,
  • Jianmin Huang,
  • Shuangning Yang,
  • Hong Li,
  • Xuan Zhao,
  • Wenjie Dong,
  • Yan Yan,
  • Song Zhao,
  • Bo Huang,
  • Bin Zhang,
  • Yi Zhang

DOI
https://doi.org/10.1080/2162402X.2017.1320011
Journal volume & issue
Vol. 6, no. 6

Abstract

Read online

CD39/CD73-adenosine pathway has been recently defined as an important tumor-induced immunosuppressive mechanism. We here documented a fraction of CD11b+CD33+ myeloid-derived suppressor cells (MDSCs) in peripheral blood and tumor tissues from non-small cell lung cancer (NSCLC) patients expressed surface ectonucleotidases CD39 and CD73. Tumor TGF-β stimulated CD39 and CD73 expression, thereby inhibited T cell and NK cell activity, and protected tumor cells from the cytotoxic effect of chemotherapy through ectonucleotidase activity. Mechanistically, TGF-β triggered phosphorylation of mammalian target of rapamycin, and subsequently activated hypoxia-inducible factor-1α (HIF-1α) that induced CD39/CD73 expression on MDSCs. CD39 and CD73 on MDSCs, therefore, link their immunosuppressive and chemo-protective effects to NSCLC progression, providing novel targets for chemo-immunotherapeutic intervention.

Keywords